Research Papers

FDA PE I

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA and 21 CFR §807.92

1. Submitter’s Name: GWOWEITechnology co., LTD.

Address: SF, No. 99, Sec. 1, Jhongcheng Rd., Shilin District, Taipei City, TAIWAN

Phone: +886-2-28380066

Fax:  +886-2-28385255

Contact:  Mr. Wilson Yeh I Manager


2. Device Name :

Trade Name: WELLGRAFT PE IResorbable Bone Void Filler

Common Name: Bone Void Filler

Classification name: filler, bone void, calcium compound


3. DEVICE CLASS

WELLGRAFT PE IResorbable Bone Void Filler have been classified as

Regulatory Class: II Product Code: MQV Panel : Orthopedic

Regulation Number: 21CFR 888.3045

4. Predicate Device: The predicate device is the

• OSTEO-G BONE VOID FILLER SYSTEM (K031319)

marketed by ASPINE USA, INC.


5. Device Description:

The WELLGRAFT PE IResorbable Bone Void Filler consists of high purity grade calcium sulfate hemihydrate powder and mixing solution. When mixed according to the directions, WELLGRAFT PE I Resorbable Bone Void Filler forms the biodegradable, biocompatible and rediopaque paste or putty, and can then be digitally applied directly or by injection into the defect site.

WELLGRAFT PE IResorbable Bone Void Filler is osteoconductive which acts as a scaffold and facilitate new bone growth. After implanted, it will be resorbed in approximately 60 90 days and be replaced by new bone during the healing process. This product is supplied sterile for single patient use.


Product: WELLGRAFT PE IResorbable Bone Void Filler


6. Intended Use:

WELLGRAFT PE IResorbable Bone Void Filler is indicated to fill bony void or gaps of the skeletal system (i.e., the extremities, spine and pelvis) that are not intrinsic to the stability of the bone structure. These defects may be surgically created osseous defects created from traumatic injury to the bone. The bone void filler resorbs and is replaced with new bone during the healing process. WELLGRAFT PEI may be used at an infected site. When used in the spine, the device is limited to posterolateral fusion procedures only.

7. Performance Summary:

The device conforms to applicable standards includes ISO 10993 series : Biological evaluation of medical devices , ASTM F2224-03 : Standard Specification for High Purity Calcium Sulfate Hemihydrate or Dihydrate for Surgical Implants & ANSVAAMI/ISO 11137 Sterilization of Health Care Products – Radiation Sterilization—-etc.

8. Conclusions:

The WELLGRAFT PE I Resorbable Bone Void Filler has the same intended use and similar technological characteristics as the OSTEO-G BONE VOID FILLER SYSTEM (K031319} marketed byASPINE USA, INC.. Moreover, bench testing contained in this submission demonstrate that any differences in their technological characteristics do not raise any new questions of safety or effectiveness. Thus, the WELLGRAFT PE IResorbable Bone Void Filler is substantially equivalent to the predicate devices.


Product:  WELLGRAFT PE I Resorbable Bone Void Filler

Public Health Service

Food and Drug Administration

9200 Corporate Boulevard

Rockville MD 20850

GWOWEl Technology Co., Ltd.

% Harvest Consulting Corporation

Ms. Jennifer Reich
2904 N. Boldt Drive
Flagstaff, AZ 8600 I

Re: K072444

Trade/Device Name: Wellgraft PE I Resorbable Bone Void Filler

Regulation Number: 21 CFR 888.3045

Regulation Narne: Resorbable calcium salt bone void filler device

Regulatory Class: II Product Code: MQV Dated: April 2, 2008

Received: April 3, 2008

Dear Ms. Reich,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for armual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further armouncements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CPR Part 807); labeling (21 CPR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CPR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CPR 1000-1050.


Page 2- Ms. Jennifer Reich

This letter will allow you to begin marketing your device as described in your Section 51O(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH’s Office of Surveillance and Biometric’s (OSB’s) Division ofPostmarket Surveillance at  (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041  or  (240) 276-3150 or the Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,
Mark N. Melkerson
Director
Division of General, Restorative and Neurological Devices
Office of Device Evaluation Center for Devices and Radiological Health
Enclosure

 

Indications for Use
510(k) Number (if known): K#072444
Device Name: WELLGRAFT PE I Resorbable Bone Void Filler
GWOWEITechnology CO., LTD.

 

Indications for Use:

WELLGRAFT PE I Resorbable Bone Void Filler is indicated to fill bony void or gaps of the skeletal system (i.e., the extremities, spine and pelvis) that are not intrinsic to the stability of the bone structure. These defects may be surgically created osseous defects created from traumatic injury to the bone. The bone void filler resorbs and is replaced with new bone during the healing process. Wellgraft PE Imay be used at an infected site. When used in the spine, the device is limited to posterolateral fusion procedures only.